All In Biotech

Drug Trial Radar · NCT06999733

A Study Comparing KB801 Verse Placebo in Patients With Stage 2 or 3 Neurotrophic Keratitis

A Phase 1/2, Multicenter, Double-Masked, Placebo-Controlled Study of KB801 in Subjects With Stage 2 or 3 Neurotrophic Keratitis

Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 7, 2025

Primary completion

Dec 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Krystal Biotech, Inc.Industry
Sponsor type
Industry
First posted
May 31, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Sponsor is developing KB801, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human nerve growth factor (NGF) to the corneas of people with Stage 2 or 3 neurotrophic keratitis (NK) via topical application. This is a Phase 1/2, multicenter, double-masked, placebo-controlled study to evaluate the safety, tolerability, and preliminary efficacy of KB801 in these subjects.

Conditions

  • Neurotrophic Keratitis

Interventions

  • KB801Biological

    Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-based vector delivering functional, full-length human nerve growth factor (NGF)

  • PlaceboDrug

    Vehicle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate safety and tolerability of KB801 based upon assessment of adverse events (frequency, severity, relatedness).Time frame: 8 weeks
  2. To evaluate the effect of KB801 on complete healing of the Persistent Corneal Epithelial Defect (PCED) in subjects with Stage 2 or Stage 3 NKTime frame: 8 weeks

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • UC Irvine Alpha Clinic

    Irvine, California · Not yet recruiting

  • Azul Vision - California Eye Specialists Medical Group Inc.

    Pasadena, California · Recruiting

  • Midwest Cornea Associates

    Carmel, Indiana · Recruiting

  • Vance Thompson Vision

    Alexandria, Minnesota · Recruiting

  • Minnesota Eye Consultants

    Minnetonka, Minnesota · Recruiting

  • St. Louis Eye Institute

    Town and Country, Missouri · Recruiting

  • Metropolitan Eye Research and Surgery Institute

    Palisades Park, New Jersey · Recruiting

  • Vance Thompson Vision

    West Fargo, North Dakota · Recruiting

  • UPMC Vision Institute

    Pittsburgh, Pennsylvania · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.